17 news items
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
VIR
29 May 24
candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
VIR
29 May 24
critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta
Evaluating Vir Biotechnology: Insights From 5 Financial Analysts
VIR
24 May 24
0
Analysts have set 12-month price targets for Vir Biotechnology, revealing an average target
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
VIR
24 May 24
HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 price target.
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
VIR
23 May 24
candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline
m02ilv54shmj fecrw6aafr4ma951r68ooeb4hptl039t7w4jxh435n0a2ow
VIR
22 May 24
Elebsiran
Elebsiran is an investigational subcutaneously administered hepatitis B virus-targeting small
5tex0uous7t1mbwncv0x2aqodsfqwxk9fo64
VIR
21 May 24
)
Elebsiran is an investigational subcutaneously administered hepatitis B virus-targeting small interfering ribonucleic
o1vjd0gh6avx
VIR
13 May 24
broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) and BRII-835 (elebsiran), an investigational HBV-targeting small
ks48ugze1p
VIR
7 May 24
1
0
0
The 12-month price targets assessed
m1zcpg9rbf8l f9g
VIR
7 May 24
HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 price target.
vrj5o36nw7si5qpojrs89af3p3jffr6
VIR
3 May 24
JP Morgan analyst Eric Joseph maintains Vir Biotechnology (NASDAQ:VIR) with a Neutral and raises the price target from $10 to $12.
diazc5sphom10l4mllt5fm557nnuu615czcrvmh
VIR
3 May 24
Needham analyst Joseph Stringer reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $15 price target.
bhyd5dkrxbdcf8 6bc8hacj07anwy4bndpsot
VIR
11 Apr 24
system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting
8v7ehxfgjy54zsvpx9i8454jqjkqecrgjmqjq2fw6l0isda8w
ANTX
VBIV
VIR
22 Mar 24
to assess and enhance HBV patients' intrinsic immunity, targeting therapies to those most likely to respond, while sparing others from poorly
1q2msgav5rs06x xj2i9z9wsp2dwi2h
VIR
15 Mar 24
Analysts have set 12-month price targets for Vir Biotechnology, revealing an average target of $64.8, a high estimate
u9hxhpag1nwab3g2ksiu0cresa0ubnw745gehy6jo
VIR
15 Mar 24
HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 price target.
d3mhzv zky
VIR
5 Mar 24
virus-targeting small interfering ribonucleic acid (siRNA) that Vir believes has the potential to stimulate an immune response and have direct antiviral
- Prev
- 1
- Next